Skip to main content
SpringerLink
Log in

Bioactive Nutritional Supplements for Chronic Kidney Disease: Potential Cost Benefits

  • Chapter
  • First Online:
Nutrients, Dietary Supplements, and Nutriceuticals

Part of the book series: Nutrition and Health ((NH))

  • 2157 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Martin JE, Sheaff MT. Renal ageing. J Pathol. 2007;211:198–205.

    Article  PubMed  CAS  Google Scholar 

  2. Harris RC, Neilson EG. Toward a unified theory of renal progression. Annu Rev Med. 2006;57:365–80.

    Article  PubMed  CAS  Google Scholar 

  3. Percy CJ, Power D, Gobe GC. Renal ageing: changes in the cellular mechanism of energy metabolism and oxidant handling. Nephrology (Carlton). 2008;13:147–52.

    Article  CAS  Google Scholar 

  4. St Peter WL. Chronic kidney disease and medicare. J Manag Care Pharm. 2007;13(Suppl D):S13–8.

    PubMed  Google Scholar 

  5. Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. Exploring the pathways leading from disadvantage to end-stage renal disease for indigenous Australians. Soc Sci Med. 2004;58:767–85.

    Article  PubMed  Google Scholar 

  6. Pat B, Hughson MD, Nicol JL, Hoy WE, Gobe GC. A comparison of pathomolecular markers of fibrosis and morphology in kidney from autopsies of African Americans and whites. Virchows Arch. 2007;450:41–50.

    Article  PubMed  CAS  Google Scholar 

  7. Hughson MD, Gobe GC, Hoy WE, Manning Jr RD, Douglas-Denton R, Bertram JF. Associations of glomerular number and birth weight with clinicopathological features of African Americans and whites. Am J Kidney Dis. 2008;52:18–28.

    Article  PubMed  Google Scholar 

  8. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol. 2003;93:P3–13.

    Article  PubMed  CAS  Google Scholar 

  9. Masajtis-Zagajewska A, Nowicki M. Influence of dual blockade of the renin-angiotensin system on thirst in hemodialysis patients. Nephron Clin Pract. 2009;112:c242–7.

    Article  PubMed  CAS  Google Scholar 

  10. Lane A, Johnson DW, Pat B, et al. Interacting roles of myofibroblasts, apoptosis and fibrogenic growth factors in the pathogenesis of renal tubulo-interstitial fibrosis. Growth Factors. 2002;20:109–19.

    Article  PubMed  CAS  Google Scholar 

  11. Wojcikowski K, Johnson DW, Gobe G. Medicinal herbal extracts – renal friend or foe? Part two: herbal extracts with potential renal benefits. Nephrology (Carlton). 2004;9:400–5.

    Article  Google Scholar 

  12. Tylicki L, Puttinger H, Rutkowski P, Rutkowski B, Horl WH. Smoking as a risk factor for renal injury in essential hypertension. Nephron Clin Pract. 2006;103(4):c121–8.

    Article  PubMed  Google Scholar 

  13. Lamacchia O, Pinnelli S, Camarchio D, et al. Waist-to-height ratio is the best anthropometric index in association with adverse cardiorenal outcomes in type 2 diabetes mellitus patients. Am J Nephrol. 2009;29:615–9.

    Article  PubMed  CAS  Google Scholar 

  14. Lu Q, Cheng LT, Wang T, et al. Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J Ren Nutr. 2008;18:495–502.

    Article  PubMed  Google Scholar 

  15. Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther Adv Cardiovasc Dis. 2007;1:27–35.

    Article  PubMed  Google Scholar 

  16. Hall AM, Unwin RJ. The not so ‘mighty chondrion’: emergence of renal diseases due to mitochondrial dysfunction. Nephron Physiol. 2007;105:1–10.

    Article  Google Scholar 

  17. Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis. 2008;13:11–32.

    Article  PubMed  CAS  Google Scholar 

  18. Nordberg M. Environmental exposure and preventive measures in Sweden and EU. Biometals. 2004;17:589–92.

    Article  PubMed  CAS  Google Scholar 

  19. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol. 2010;105(1 Suppl):30A–5.

    Article  PubMed  CAS  Google Scholar 

  20. Komers R. What is the role of renin inhibition in the treatment of diabetic kidney disease? Curr Diab Rep. 2009;9:447–52.

    Article  PubMed  CAS  Google Scholar 

  21. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes. 2007;115:69–84.

    Article  PubMed  CAS  Google Scholar 

  22. González-Périz A, Horrillo R, Ferré N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009;23:1946–57.

    Article  PubMed  CAS  Google Scholar 

  23. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009;116:87–98.

    Article  Google Scholar 

  24. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role. Nat Rev Nephrol. 2009;5:375–83.

    Article  PubMed  CAS  Google Scholar 

  25. Fellström B, Holdaas H, Jardine AG, et al. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin. 2009;25:271–85.

    Article  PubMed  CAS  Google Scholar 

  26. Fathi R, Isbel N, Short L, et al. The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis. 2004;43:45–52.

    Article  PubMed  CAS  Google Scholar 

  27. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107:2646–52.

    Article  PubMed  Google Scholar 

  28. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999;10:2177–84.

    PubMed  CAS  Google Scholar 

  29. Percy C, Pat B, Poronnik P, Gobe G. Role of oxidative stress in age-associated chronic kidney pathologies. Adv Chronic Kidney Dis. 2005;12:78–83.

    Article  PubMed  Google Scholar 

  30. Thaha M, Widodo, Pranawa W, Yogiantoro M, Tomino Y. Intravenous N-acetyl-cysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Clin Nephrol. 2008;69:24–32.

    PubMed  CAS  Google Scholar 

  31. Prasad K. Vitamin E does not regress hypercholesterolemic atherosclerosis. J Cardiovasc Pharmacol Ther. 2009;14:231–41.

    Article  PubMed  CAS  Google Scholar 

  32. Machlin LJ, Gabriel E. Kinetics of tissue alpha-tocopherol uptake and depletion following administration of high levels of vitamin E. Ann NY Acad Sci. 1982;393:48–60.

    Article  PubMed  CAS  Google Scholar 

  33. Machlin LJ. Clinical uses of vitamin E. Acta Vitaminol Enzymol. 1985;7(Suppl):33–43.

    PubMed  Google Scholar 

  34. Baker H, Frank B, Feingold S, de Angelis S. Plasma tocopherol in man at various times after ingesting free or acetylated tocopherol. Nutr Rep Internat. 1980;21:531–6.

    CAS  Google Scholar 

  35. Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta. 2003;338:91–8.

    Article  PubMed  CAS  Google Scholar 

  36. Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis. 2000;150:217–24.

    Article  PubMed  CAS  Google Scholar 

  37. Akiyama S, Inagaki M, Tsuji M, et al. Comparison of effect of vitamin E-coated dialyzer and oral vitamin E on hemodialysis-induced Cu/Zn-superoxide dismutase. Am J Nephrol. 2005;25:500–6.

    Article  PubMed  CAS  Google Scholar 

  38. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.

    PubMed  CAS  Google Scholar 

  39. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842–57.

    Article  PubMed  CAS  Google Scholar 

  40. Blatt DH, Pryor WA. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:150–1.

    PubMed  Google Scholar 

  41. Hemila H. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:151–2.

    PubMed  Google Scholar 

  42. Krishnan K, Campbell S, Stone WL. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:151. author reply 156–158.

    PubMed  Google Scholar 

  43. Marras C, Lang AE, Oakes D, et al. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:152–3.

    PubMed  Google Scholar 

  44. Lim WS, Liscic R, Xiong C, Morris JC. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:152.

    PubMed  Google Scholar 

  45. DeZee KJ, Shimeall W, Douglas K, Jackson JL. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:153–4. author reply 156–158.

    PubMed  Google Scholar 

  46. Meydani SN, Lau J, Dallal GE, Meydani M. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:153. author reply 156–158.

    PubMed  Google Scholar 

  47. Possolo AM. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:154. author reply 156–158.

    PubMed  Google Scholar 

  48. Baggott JE. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:155–6. author reply 156–158.

    PubMed  Google Scholar 

  49. Carter T. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:155. author reply 156–158.

    PubMed  Google Scholar 

  50. Jialal I, Devaraj S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005;143:155. author reply 156–158.

    PubMed  Google Scholar 

  51. Huang HY, Appel LJ. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. J Nutr. 2003;133:3137–40.

    PubMed  CAS  Google Scholar 

  52. Corrigan Jr JJ, Marcus FI. Coagulopathy associated with vitamin E ingestion. JAMA. 1974;230:1300–1.

    Article  PubMed  Google Scholar 

  53. Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci USA. 1995;92:8171–5.

    Article  PubMed  CAS  Google Scholar 

  54. Megavitamin E. supplementation and vitamin K-dependent carboxylation. Nutr Rev. 1983;41:268–70.

    Google Scholar 

  55. Ikizler TA. Nutrition, inflammation and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17:162–7.

    Article  PubMed  CAS  Google Scholar 

  56. Fetterman Jr JW, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm. 2009;66:1169–79.

    Article  PubMed  CAS  Google Scholar 

  57. Panzetta O, Cominacini L, Garbin U, et al. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol. 1995;44:303–9.

    PubMed  CAS  Google Scholar 

  58. Barbosa V, Miles E, Calhau C, Lafuente E, Calder P. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled trial. Crit Care. 2010;14:R5. doi:10.1186/cc8844.

    Article  PubMed  Google Scholar 

  59. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320:265–71.

    Article  PubMed  CAS  Google Scholar 

  60. Hughes DA, Pinder AC, Piper Z, Johnson IT, Lund EK. Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. Am J Clin Nutr. 1996;63:267–72.

    PubMed  CAS  Google Scholar 

  61. Fassett R, Gobe G, Peake J, Coombes J. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis. 2010;56:728–42.

    Google Scholar 

  62. Liani M, Salvati F, Golato M, et al. Immunological effects of fish oil on patients with end-stage renal disease. Nephron. 1995;69:86–90.

    Article  PubMed  CAS  Google Scholar 

  63. Mayer K, Fegbeutel C, Hattar K, et al. Omega-3 versus omega-6 lipid emulsions exert differential influence on neutrophils in septic shock: impact of fatty acids and lipid mediator generation. Intensive Care Med. 2003;29:1472–81.

    Article  PubMed  Google Scholar 

  64. Tappt L, Berger M, Schwartz J, et al. Metabolic effects of parenteral nutrition enriched with n-3 polyunsaturated fatty acids in critically ill patients. Clin Nutr. 2006;25:588–95.

    Article  CAS  Google Scholar 

  65. Blackhall ML, Coombes JS, Fassett R. The relationship between antioxidant supplements and oxidative stress in renal transplant recipients: a review. ASAIO J. 2004;50:451–7.

    Article  PubMed  CAS  Google Scholar 

  66. Wojcikowski K, Stevenson L, Leach D, Wohlmuth H, Gobe G. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process. J Altern Complement Med. 2007;13:103–9.

    Article  PubMed  Google Scholar 

  67. Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. J Agric Food Chem. 2005;53:1841–56.

    Article  PubMed  CAS  Google Scholar 

  68. Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53:4290–302.

    Article  PubMed  CAS  Google Scholar 

  69. Saenger AK, Laha TJ, Edenfield MJ, Sadrzadeh SM. Quantification of urinary 8-iso-PGF2alpha using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem. 2007;40:1297–304.

    Article  PubMed  CAS  Google Scholar 

  70. Cottone S, Mulè G, Guarneri M, et al. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant. 2009;24:497–503.

    Article  PubMed  CAS  Google Scholar 

  71. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomized placebo-controlled trial. Lancet. 2000;356:1213–8.

    Article  PubMed  CAS  Google Scholar 

  72. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154–60.

    Article  PubMed  CAS  Google Scholar 

  73. Procopio A, Alcaro S, Nardi M, et al. Synthesis, biological evaluation, and molecular modeling of oleuropein and its semisynthetic derivatives as cyclooxygenase inhibitors. J Agric Food Chem. 2009;57:11161–7.

    Article  PubMed  CAS  Google Scholar 

  74. Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun. 2007;362:793–8.

    Article  PubMed  CAS  Google Scholar 

  75. Zhong L, Furne JK, Levitt MD. An extract of black, green, and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers. Am J Clin Nutr. 2006;84:551–5.

    PubMed  CAS  Google Scholar 

  76. Kamgar M, Zaldivar F, Vaziri ND, Pahl MV. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc. 2009;101:336–44.

    PubMed  Google Scholar 

  77. Wojcikowski K, Johnson DW, Gobe G. Medicinal herbal extracts renal friend or foe? Part one: the toxicities of medicinal herbs. Nephrology (Carlton). 2004;9:313–8.

    Article  CAS  Google Scholar 

  78. Gabardi S, Munz K, Ulbricht C. A review of dietary supplement-induced renal dysfunction. Clin J Am Soc Nephrol. 2007;2:757–65.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Kidney Disease Research, School of Medicine, The University of Queensland, Building 33, Princess Alexandra Hospital, Woolloongabba, 4102, Brisbane, QLD, Australia

    Glenda C. Gobe

Authors
  1. Glenda C. Gobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert G. Fassett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeff S. Coombes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenda C. Gobe .

Editor information

Editors and Affiliations

  1. University of Arizona Mel and Enid Zucke, 1295 N. Martin, Tucson, 85724-5155, USA

    Joe K Gerald

  2. Arizona Health Science Center, Mel and Enid Zuckerman College of Public, University of Arizona, 1501 N. Campbell Ave. Room 4335, Tucson, 85724-5155, Arizona, USA

    Ronald Ross Watson

  3. Dept. Nutrition & Dietetics, King's College, Stamford St. 150, London, SE1 9NH, United Kingdom

    Victor R. Preedy

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gobe, G.C., Fassett, R.G., Coombes, J.S. (2011). Bioactive Nutritional Supplements for Chronic Kidney Disease: Potential Cost Benefits. In: Gerald, J., Watson, R., Preedy, V. (eds) Nutrients, Dietary Supplements, and Nutriceuticals. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60761-308-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-308-4_19

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-307-7

  • Online ISBN: 978-1-60761-308-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation